Detalles de la búsqueda
1.
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
Br J Haematol
; 200(4): 440-450, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335916
2.
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
Ann Hematol
; 102(5): 1099-1109, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36959485
3.
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Haematologica
; 107(6): 1410-1426, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34670358
4.
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
Cancer
; 127(12): 2015-2024, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739457
5.
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation.
Eur J Haematol
; 107(5): 573-582, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297437
6.
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
Am J Hematol
; 96(2): 234-240, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33146914
7.
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
Haematologica
; 105(10): 2420-2431, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33054082
8.
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
Biol Blood Marrow Transplant
; 24(1): 119-126, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024804
9.
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Haematologica
; 103(1): 80-90, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29025907
10.
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies.
Mycoses
; 61(9): 650-655, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29693758
11.
Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.
Infection
; 45(4): 505-511, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28353153
12.
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Am J Hematol
; 91(8): 755-62, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27084986
13.
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Br J Haematol
; 186(6): e223-e225, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31348524
14.
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Br J Haematol
; 184(3): 457-460, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29359798
15.
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Br J Haematol
; 164(5): 710-6, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24344981
16.
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Ann Hematol
; 93(12): 2011-8, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24989345
17.
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.
Hematol Oncol
; 36(2): 498-499, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29052244
18.
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Ann Hematol
; 92(10): 1309-18, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23686116
19.
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
Am J Hematol
; 93(2): E33-E35, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29080220
20.
Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Front Immunol
; 14: 1111419, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36865545